← FDA DRUG APPROVALS

FDA ANDA · ANDA091338

LEVETIRACETAM

Sponsor: TORRENT PHARMS LTD

APPLICATION
ANDA091338
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-29
LATEST ACTION
2021-06-08
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

LEVETIRACETAMPrescription
LEVETIRACETAM 750MG · TABLET, EXTENDED RELEASE · ORAL
LEVETIRACETAMPrescription
LEVETIRACETAM 500MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2021-06-08Labeling · Supplement 16 · standardAP
2020-09-18Labeling · Supplement 12 · standardAP
2020-09-18Labeling · Supplement 15 · standardAP
2020-09-18Labeling · Supplement 13 · standardAP
2015-08-13Labeling · Supplement 7 · standardAP
2015-08-13Labeling · Supplement 8 · standardAP
2014-11-04Labeling · Supplement 5 · standardAP
2014-11-04Labeling · Supplement 6 · standardAP
2012-05-29OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →